EGFR and cancer: However, current data suggests that this approach is associated with a disappointing response rate of approximately 10% [11,12], and that the overall survival benefit is marginal even when the study included those patients whose cancers carried driver mutations such as epidermal growth factor receptor (EGFR) mutations, and who were treated with matched therapy [11].